Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.57 |
| ▸ | DRD3 | P35462 | 9/20 | 0.56 |
| ▸ | DRD4 | P21917 | 8/20 | 0.53 |
| ▸ | HTR1A | P08908 | 6/20 | 0.53 |
| ▸ | DRD1 | P21728 | 6/20 | 0.53 |
| ▸ | DRD5 | P21918 | 6/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PRCP | P42785 | 1/20 | 0.53 |
| ▸ | EBP | Q15125 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973130 | 1.00 | DRD2 (0.57) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL29744881 | 1.00 | DRD2 (0.57) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL1342921 | 1.00 | DRD2 (0.57) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL9205714 | 1.00 | DRD2 (0.57) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL28784359 | 1.00 | DRD2 (0.57) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL1424708 | 1.00 | DRD2 (0.57) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL27749604 | 0.80 | DRD2 (0.50) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL10274630 | 0.79 | DRD2 (0.69) | DRD2DRD3DRD4HTR1ADRD1 | |
| Ammonia Solution, Strong SCHEMBL3406155 | 0.79 | DRD2 (0.49) | DRD2DRD3DRD4HTR1ADRD1 | |
| Hydrochloric Acid SCHEMBL27854009 | 0.78 | DRD2 (0.47) | DRD2DRD3DRD4HTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363630-B1 | KAPPA OPIOID RECEPTOR LIGANDS | RES TRIANGLE INST (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1363630-A4 | KAPPA OPIOID RECEPTOR LIGANDS | RES TRIANGLE INST (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6974824-B2 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1363630-A2 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020132828-A1 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2002053533-A2 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2002-07-11 | — | — | WO | disclosed |
| EP-0506468-B1 | N-substituted 4-phenyl-piperidine opioid-antagonists | LILLY CO ELI (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5270328-A | Peripherally selective piperidine opioid antagonists | ELI LILLY AND COMPANY (US) | 1993-12-14 | — | — | US | disclosed |
| US-5159081-A | INTERMEDIATES OF PERIPHERALLY SELECTIVE N-CARBONYL-3,4,4-TRISUBSTITUTED PIPERIDINE OPIOID ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0506468-A1 | N-substituted 4-phenyl-piperidine opioid-antagonists | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132828-A1 | Kappa opioid receptor ligands | OPRK1, OPRD1, OPRM1 | DRD2 256/4885DRD3 218/4885DRD4 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.